MATTHEW J WHITTERS
Broker in Hudson, MA
License number
Massachusetts 9526068
Issued Date
Feb 8, 2013
Expiration Date
Oct 16, 2015
Type
Salesperson
Address
Address
Hudson, MA 01749
Professional information
Method Of Treating Or Ameliorating An Immune Cell Associated Pathology Using Gitr Ligand Antibodies
US Patent:
7618632, Nov 17, 2009
Filed:
May 24, 2004
Appl. No.:
10/853032
Inventors:
Mary Collins - Natick MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US
Assignee:
Wyeth - Madison NJ
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/395, C07K 16/00
US Classification:
4241441, 53038822
Abstract:
The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e. g. , autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
Gitr Ligand And Gitr Ligand-Related Molecules And Antibodies And Uses Thereof
US Patent:
2010008, Apr 1, 2010
Filed:
Aug 28, 2009
Appl. No.:
12/550244
Inventors:
Mary Collins - Natick MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US
Assignee:
Wyeth - Madison NJ
The Government of the United States - Rockville MD
The Government of the United States - Rockville MD
International Classification:
A61K 39/395, C07H 21/04, A01K 67/00, C07K 14/435, C07H 21/02, G01N 33/53, C12Q 1/68, C12N 5/02, A61K 35/12
US Classification:
4241441, 536 235, 800 13, 530350, 536 245, 435 71, 435 6, 435375, 424 9371
Abstract:
The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
Cd25+ Differential Markers And Uses Thereof
US Patent:
2008022, Sep 11, 2008
Filed:
Jan 31, 2008
Appl. No.:
12/023470
Inventors:
Michael Chapman Byrne - Brookline MA, US
Ethan Menahem Shevach - Rockville MD, US
Mary Collins - Natick MA, US
Rebecca Suzanne McHugh - Auburn CA, US
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Ethan Menahem Shevach - Rockville MD, US
Mary Collins - Natick MA, US
Rebecca Suzanne McHugh - Auburn CA, US
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Assignee:
WYETH - Madison NJ
The Government USA, as respresented by the Secretary, Department of Health - Rockville MD
The Government USA, as respresented by the Secretary, Department of Health - Rockville MD
International Classification:
A61K 38/00, C12N 5/06, A61P 37/00
US Classification:
514 2, 435375
Abstract:
The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.
Methods Of Inhibiting Binding And Treating Ig-Mediated Responses With Il-13 Receptor
US Patent:
6248714, Jun 19, 2001
Filed:
Apr 30, 1997
Appl. No.:
8/846340
Inventors:
Mary Collins - Natick MA
Debra Donaldson - Medford MA
Lori Fitz - Arlington MA
Tamlyn Neben - Acton MA
Matthew Whitters - Hudson MA
Clive Wood - Boston MA
Debra Donaldson - Medford MA
Lori Fitz - Arlington MA
Tamlyn Neben - Acton MA
Matthew Whitters - Hudson MA
Clive Wood - Boston MA
Assignee:
Genetics Institute, Inc. - Cambridge MA
International Classification:
A61K 3800, G01N 3353
US Classification:
514 2
Abstract:
IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.
Antagonizing Interleukin-21 Receptor Activity
US Patent:
2008024, Oct 2, 2008
Filed:
Nov 29, 2007
Appl. No.:
11/947425
Inventors:
Deborah A. Young - Melrose MA, US
Mary Collins - Natick MA, US
Kyriaki Dunussi-Joannopoulos - Belmont MA, US
Richard Michael O'Hara - Quincy MA, US
Marion T. Kasaian - Charlestown MA, US
Matthew J. Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Kyriaki Dunussi-Joannopoulos - Belmont MA, US
Richard Michael O'Hara - Quincy MA, US
Marion T. Kasaian - Charlestown MA, US
Matthew J. Whitters - Hudson MA, US
Assignee:
WYETH - Madison NJ
International Classification:
A61K 38/20, A61K 39/395, A61K 39/44, C07K 16/46, C12N 15/63, C12N 5/06, C12P 21/00, A61P 41/00
US Classification:
424 852, 4241581, 4241391, 4241781, 5303917, 4353201, 435325, 435 697
Abstract:
Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).
Methods Of Using Antibodies To Human Il-13Bc For Inhibiting Il-13 Binding
US Patent:
7674591, Mar 9, 2010
Filed:
Feb 27, 2006
Appl. No.:
11/362028
Inventors:
Mary Collins - Natick MA, US
Debra Donaldson - Medford MA, US
Lori Fitz - Arlington MA, US
Tamlyn Neben - Acton MA, US
Matthew Whitters - Hudson MA, US
Clive Wood - Boston MA, US
Debra Donaldson - Medford MA, US
Lori Fitz - Arlington MA, US
Tamlyn Neben - Acton MA, US
Matthew Whitters - Hudson MA, US
Clive Wood - Boston MA, US
Assignee:
Genetics Institute, LLC - Cambridge MA
International Classification:
G01N 33/567, A61K 39/395, C07K 14/715, C12P 21/06
US Classification:
435 71, 4241451, 514 12, 530351, 536 235
Abstract:
Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
Treatment Of Fibrosis By Antagonism Of Il-13 And Il-13 Receptor Chains
US Patent:
7282206, Oct 16, 2007
Filed:
Sep 25, 2003
Appl. No.:
10/671034
Inventors:
Thomas A. Wynn - Silver Spring MD, US
Monica G. Chiaramonte - Rockville MD, US
Mary Collins - Natick MA, US
Debra Donaldson - Medford MA, US
Lori Fitz - Arlington MA, US
Tamlyn Neben - Walnut Creek CA, US
Matthew J. Whitters - Hudson MA, US
Clive Wood - Boston MA, US
Monica G. Chiaramonte - Rockville MD, US
Mary Collins - Natick MA, US
Debra Donaldson - Medford MA, US
Lori Fitz - Arlington MA, US
Tamlyn Neben - Walnut Creek CA, US
Matthew J. Whitters - Hudson MA, US
Clive Wood - Boston MA, US
Assignee:
Wyeth - Madison NJ
The United States of America as represented by the Department of Health and Human Services - Washington DC
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/395, A61K 39/00
US Classification:
4241451, 4241301, 4241341, 4241411, 4241421, 514 12
Abstract:
Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.
Methods And Compositions For Modulating T Helper (T) Cell Development And Function
US Patent:
7731946, Jun 8, 2010
Filed:
Nov 12, 2007
Appl. No.:
11/938618
Inventors:
Michael J. Grusby - Newton MA, US
Andrea Wurster - Arlington MA, US
Deborah Young - Melrose MA, US
Mary Collins - Natick MA, US
Matthew Whitters - Hudson MA, US
Andrea Wurster - Arlington MA, US
Deborah Young - Melrose MA, US
Mary Collins - Natick MA, US
Matthew Whitters - Hudson MA, US
Assignee:
Wyeth LLC - Madison NJ
The President and Fellows of Harvard College - Cambridge MA
The President and Fellows of Harvard College - Cambridge MA
International Classification:
A61K 38/20, A61K 38/17, C07K 14/47
US Classification:
424 852, 424 851, 514 12, 514 2, 530351
Abstract:
Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e. g. , human IL-21, activity or level.
Method And Compositions For Treating Asthma
US Patent:
7553487, Jun 30, 2009
Filed:
Nov 15, 2004
Appl. No.:
10/989313
Inventors:
Mary Collins - Natick MA, US
Debra Donaldson - Medford MA, US
Lori Fitz - Arlington MA, US
Tamlyn Neben - Walnut Creek CA, US
Matthew J. Whitters - Hudson MA, US
Clive Wood - Boston MA, US
Debra Donaldson - Medford MA, US
Lori Fitz - Arlington MA, US
Tamlyn Neben - Walnut Creek CA, US
Matthew J. Whitters - Hudson MA, US
Clive Wood - Boston MA, US
Assignee:
Genetics Institute, LLC - Madison NJ
The Johns Hopkins University - Baltimore MD
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/00, C07K 14/54
US Classification:
4241341, 530351
Abstract:
The present invention is directed to methods for treating asthma.
Arthritis-Associated B Cell Gene Expression
US Patent:
2009002, Jan 22, 2009
Filed:
Aug 16, 2007
Appl. No.:
11/893933
Inventors:
David Johannes von Schack - Arlington MA, US
Matthew James Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Eugene Lee Brown - Newton MA, US
Matthew James Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Eugene Lee Brown - Newton MA, US
Assignee:
Wyeth - Madison NJ
International Classification:
C07K 16/18, C07K 16/40, A61K 39/395, A61P 19/02
US Classification:
4241451, 435 6, 435455, 435375, 5303871, 5303882, 53038826, 4241581, 4241461
Abstract:
The invention features methods and compositions benefiting from differential gene expression observed in arthritis-associated B cells.